Skip to main content
. 2023 Nov 13;7(4):e294–e302. doi: 10.1055/s-0043-1776328

Table 1. Baseline characteristics of the no AF and AF populations.

No AF AF p
n 30 75
Median age (Q 1 –Q 3 ) 76 (60–85) 74 (66–79) 0.55
Female (%) 60.0 38.7 0.08
Known AF (%) Excluded 84.0
Mean hemoglobin (g\L) ± SD 137.3 ± 15.6 134.0 ± 20.2 0.42
Mean platelet count (10 × 9/L) ± SD 247.4 ± 60.1 247.0 ± 80.1 0.98
Mean platelet volume (fL) ± SD 10.7 ± 0.9 10.6 ± 1.0 0.76
Median admission NEWS score (Q 1 –Q 3 ) 1 (0–2) 1 (1–2) 0.15
Deaths within 6 months (%) 0 (0) 0 (0)
Vascular events within 6 months (%) 0 (0) 0 (0)
Risk factors for thrombotic disease, n (%)
 Congestive cardiac failure 6 (20.0) 22 (29.3) 0.46
 Hypertension 16 (53.3) 51 (68.0) 0.24
 Diabetes 7 (23.3) 19 (25.3) 0.83
 Ischemic heart disease 6 (20.0) 14 (18.6) 0.88
 Hypercholesterolemia 8 (26.7) 31 (41.3) 0.24
 Stroke in past 10 years 0 (0) 0 (0)
 Median CHA 2 DS 2 -VASc score 3 (1–5) 3 (2–4) 0.92
Admission medication, n (%)
 ACE inhibitor or ARB 8 (26.7) 28 (37.3) 0.42
 Aspirin 5 (16.7) 14 (18.6) 0.81
 Clopidogrel 6 (20.0) 3 (4.0) 0.02
 Apixaban 1 (3.3) 9 (12.0) 0.32
 Dabigatran 0 (0) 1 (1.3) 0.50
 Rivaroxaban 0 (0) 25 (33.3) 0.0008
 Warfarin 0 (0) 12 (16.0) 0.05
 Statin 10 (30.0) 34 (45.3) 0.36
Serum biomarkers, median (Q 1 –Q 3 )
 Median d-dimer (ng/mL) 158 (80–387)
 Median fibrinogen (g/L) 3.71 (2.89–4.72)
 Median BNP (pg/mL) 2254 (623–4467)
 Median hs-CRP (mg/L) 24.8 (16.3–30.6)

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, N-terminal pro b-type natriuretic peptide; hs-CRP, high-sensitivity C-reactive protein.

Note: Median values are presented with interquartile range (Q 1 –Q 3 ) and mean values with standard deviation (SD). p -Values were calculated using a paired t -test for parametric and Mann–Whitney U test for nonparametric continuous data and Chi-squared test for categorical data. Statistically significant p -values are indicated in bold.